+1 (437) 886-5136
Remember me?
Adiponectin: mechanistic insights and clinical implications. Turer AT & Scherer PE. Diabetologia. 2012 55(9):2319-26.
Protective role of adiponectin in cardiovascular disease. Shibata R, Murohara T, Ouchi N. Curr Med Chem. 2012 19(32):5459-66
Adiponectin, an anti-carcinogenic hormone? A systematic review on breast, colorectal, liver and prostate cancer. Perrier S, Jardé T. Curr Med Chem. 2012 19(32):5501-12
Signaling mechanisms underlying the insulin-sensitizing effects of adiponectin. Cheng KK, Lam KS, Wang B, Xu A. Best Pract Res Clin Endocrinol Metab. 2014 28(1):3-13
APPL1: role in adiponectin signaling and beyond. Deepa SS, Dong LQ. Am J Physiol Endocrinol Metab. 2009 296(1):E22-36
Should C-reactive protein be a target of therapy? Oh J, Teoh H, Leiter LA. Diabetes Care. 2011 May;34 Suppl 2:S155-60.
High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link? Yousuf O, et al. J Am Coll Cardiol. 2013 Jul 30;62(5):397-408
Cystatin C: an emerging biomarker in cardiovascular disease. Angelidis C, et al. Curr Top Med Chem. 2013;13(2):164-79.
Update on cystatin C: incorporation into clinical practice. Shlipak MG, Mattes MD, Peralta CA. Am J Kidney Dis. 2013 62(3):595-603.
The human fatty acid-binding protein family: evolutionary divergences and functions. Smathers RL, Petersen DR. Hum Genomics. 2011 Mar;5(3):170-91.
The structural biology of the FGF19 subfamily. Beenken A, Mohammadi M. Adv Exp Med Biol. 2012;728:1-24.
Mini-review: endocrine actions of fibroblast growth factor 19. Jones S. Mol Pharm. 2008 Jan-Feb;5(1):42-8
Stressed Liver and Muscle Call on Adipocytes with FGF21. Luo Y, McKeehan WL. Front Endocrinol 2013 18;4:194
Fibroblast growth factor 21 as an emerging metabolic regulator: clinical perspectives. Woo YC, Xu A, Wang Y, Lam KS. Clin Endocrinol (Oxf). 2013 Apr;78(4):489-96
Molecular mechanisms of insulin resistance in diabetes. Soumaya K. Adv Exp Med Biol. 2012;771:240-51.
The links between insulin resistance, diabetes, and cancer. Orgel E, Mittelman SD. Curr Diab Rep. 2013 13(2):213-22
Irisin as a muscle-derived hormone stimulating thermogenesis – A critical update. Hofmann T, Elbelt U, Stengel A. Peptides. 2014 26;54C:89-100
Muscles, exercise and obesity: skeletal muscle as a secretory organ. Pedersen BK, Febbraio MA. Nat Rev Endocrinol. 2012 8(8):457-65
Emerging clinical and experimental evidence for the role of lipocalin-2 in metabolic syndrome. Jang Y, Lee JH, Wang Y, Sweeney G. Clin Exp Pharmacol Physiol. 2012 Feb;39(2):194-9
The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer. Chakraborty S, Kaur S, Guha S, Batra SK. Biochim Biophys Acta. 2012 Aug;1826(1):129-69.
Major urinary protein-1 increases energy expenditure and improves glucose intolerance through enhancing mitochondrial function in skeletal muscle of diabetic mice. Hui X, et al J Biol Chem. 2009 May 22;284(21):14050-7.
PI3K-PKB/Akt pathway. Hemmings BA, Restuccia DF. Cold Spring Harb Perspect Biol. 2012 4(9):a011189
Akt, FoxO and regulation of apoptosis. Zhang X, Tang N, Hadden TJ, Rishi AK. Biochim Biophys Acta. 2011 1813(11):1978-86
Akt signalling in health and disease. Hers I, Vincent EE, Tavaré JM. Cell Signal. 2011 Oct;23(10):1515-27.
Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions. Cesari M, Pahor M, Incalzi RA. Cardiovasc Ther. 2010 28(5):e72-91.
The plasminogen activation system: new targets in lung inflammation and remodeling. Schuliga M, Westall G, Xia Y, Stewart AG. Curr Opin Pharmacol. 2013 13(3):386-93
The metabolic role of retinol binding protein 4: an update. Christou GA, Tselepis AD, Kiortsis DN. Horm Metab Res. 2012 44(1):6-14.
RBP4: a controversial adipokine. Kotnik P, Fischer-Posovszky P, Wabitsch M. Eur J Endocrinol. 2011 Nov;165(5):703-11
© 2022 · Toronto Bioscience. Theme by HB-Themes.
